Literature DB >> 25898691

Association between CC motif chemokine ligand 5 (CCL5) polymorphisms and asthma risk: an updated meta-analysis.

H Huang, W Nie, Y Zang, J Chen, Q Xiu.   

Abstract

BACKGROUND: Findings regarding the associations between the CC motif chemokine ligand 5 (CCL5) -403G/A and -28C/G polymorphisms and asthma risk are controversial.We performed a meta-analysis to determine whether CCL5 polymorphisms are associated with asthma risk.
METHODS: We searched the Pubmed, Embase, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases for studies published before June 2013. The strength of associations was calculated using ORs with 95% CIs.
RESULTS: Twenty case-control studies were included in this meta-analysis. We did not observe a significant association between the CCL5 -403G/A polymorphism and asthma risk (OR, 1.10; 95% CI, 0.93-1.30; P = .25). The CCL5 - 28C/G polymorphism, however, was associated with a significantly elevated asthma risk (OR, 1.17; 95% CI, 1.02-1.33; P = .02). Subgroup analyses found that the CCL5 -28C/G polymorphism was significantly associated with asthma risk in Asians (OR, 1.16; 95% CI, 1.01-1.33; P = .04) and children (OR, 1.29; 95% CI, 1.03-1.63; P = .03).
CONCLUSIONS: This meta-analysis suggests that the CCL5 -28C/G polymorphism is a risk factor for asthma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25898691

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  2 in total

1.  Wentong decoction cures allergic bronchial asthma by regulating the apoptosis imbalance of EOS.

Authors:  Yue Yan; Hai-Peng Bao; Chun-Lei Li; Qi Shi; Yan-Hua Kong; Ting Yao; You-Lin Li
Journal:  Chin Med       Date:  2018-04-18       Impact factor: 5.455

2.  Association of RANTES gene polymorphisms with susceptibility to childhood asthma: A meta-analysis.

Authors:  Yan-Qin Zhang; Xiu-Xiang Gao
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.